Clinical Trials Logo
  1. Home
  2. Platelet Aggregation Inhibitors
  3. NCT04328883

Pharmacodynamics and Pharmacokinetics of Aspirin Inhalation Powder With Non-Enteric-Coated Chewable Aspirin

Platelet Aggregation Inhibitors Clinical Trial

Official title:
A Phase 1, Single-dose, Open-label, Pilot Study to Compare the Pharmacodynamics and Pharmacokinetics of Acetylsalicylic Acid Inhalation Powder With Non-Enteric-Coated Chewable Aspirin in Healthy Adults

Clinical Trial Summary

ASA inhalation powder is an inhaled nonsteroidal anti-inflammatory drug-device combination that has been developed to reduce the risk of vascular mortality in patients with suspected acute myocardial infarction (MI), an FDA approved indication for oral formulations of aspirin.

The primary goal of study OTP-P0-926 is to collect pharmacokinetic (PK)and pharmacodynamics (PD) pilot data to determine onset and extent of aspirin response after administration of varying doses of inhaled ASA (50-100mg) and 162 mg Non-Enteric-Coated Chewable ASA. PD will be assessed using standard methods to measure platelet inhibition by aspirin including platelet aggregation, serum thromboxane,and urinary thromboxane. Furthermore, the pharmacokinetics (PK) of ASA will be determined and compared to PD measurements. Results of this pilot study will guide dosing in a subsequent larger Phase II study.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04328883
Study type Interventional
Source Inova Health Care Services
Contact
Status Completed
Phase Phase 1
Start date July 16, 2019
Completion date October 10, 2019
View Details
See also
  Status Clinical Trial Phase
Completed NCT02554006 - Predischarge Bundle to Minimize Negative Impact on Quality of Life of Nuisance Bleedings N/A
Recruiting NCT04796714 - AntiPlatelet theraPy stratEgy followiNg Left Atrial appenDAGe closurE Phase 4
Completed NCT02711410 - The Influence of CYP2C19 Polymorphism and Clinical Outcomes in Stroke Patients N/A
Completed NCT05278637 - GM03 - Platelet RNA Signatures of Aspirin Early Phase 1
Recruiting NCT03288441 - Management and Outcomes of Anti-thrombotic Medication Use in Thrombocytopenia
Recruiting NCT05306951 - Correct Timing of Head Imaging in Trauma
Recruiting NCT05732701 - Algorithm-based Tailoring of Dual Antiplatelet Therapy to Improve Outcomes Following Percutaneous Coronary Interventions N/A
Recruiting NCT05702463 - Assessing Pharmacokinetics and Pharmacodynamics of Daily Enteric-coated Aspirin in Patients With StablE Diabetes II Phase 1
Not yet recruiting NCT03862651 - Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoing Surgery (MONET BRIDGE) Phase 2
Completed NCT01354808 - ACCEL-LOADING-ACS Study Phase 4
Completed NCT00799396 - Determining Genetic Role in Treatment Response to Anti-Platelet Interventions (The PAPI Study) Phase 4
Completed NCT00325390 - Efficacy and Safety in Patients With Acute Coronary Syndrome Without ST-Segment Elevation Phase 3
Completed NCT04999293 - Ticagrelor in Elderly Patients Undergoing Percutaneous Coronary Intervention
Completed NCT02808767 - Comparison of Prasugrel and Ticagrelor in the Treatment of Acute Myocardial Infarction Phase 4
Completed NCT00769938 - WOEST ( What is the Optimal antiplatElet & Anticoagulant Therapy in Patients With Oral Anticoagulation and Coronary StenTing) Phase 4
Completed NCT03599284 - The Efficacy, Safety and Pharmacokinetic of Antiplatelet Therapy for Vicagrel Phase 2
Completed NCT03785509 - The Compliance of DAPT and Statins on Clinical Outcomes in Percutaneous Coronary Intervention Patients
Unknown status NCT01103843 - Plavix, Prasugrel and Drug Eluting Stents Pilot Trial N/A
Active, not recruiting NCT03462498 - ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study for the Patients With ACS Phase 4